Literature DB >> 6725600

Antithrombin III metabolism in patients with liver disease.

E Knot, J W Ten Cate, H R Drijfhout, L H Kahlé, G N Tytgat.   

Abstract

Liver diseases are associated with complex haemostasis defects, in which platelets, coagulation, and fibrinolysis may all be affected. The low plasma concentrations of clotting factors often found can be the result of many changes such as impaired synthesis, increased catabolism due to intravascular coagulation, or alternate distribution. In this study, we investigated the metabolism of purified human antithrombin III(AT III) labelled with 125I in 25 patients with histologically established liver disease and in nine control subjects. The results showed that, in general, low plasma concentrations of AT III in liver cirrhosis are not due to consumption in the central compartment but rather to altered transcapillary flux ratio. Such altered transcapillary flux ratios may already exist even with normal plasma AT III concentrations. Altered ratios are not only found for coagulation proteins but also for albumin and thus may be a general phenomenon of liver disease. In micronodular cirrhosis the alpha phase, the transcapillary efflux (k1, 2) and influx (k2, 1) were significantly increased compared with the normal subjects.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6725600      PMCID: PMC498774          DOI: 10.1136/jcp.37.5.523

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  37 in total

Review 1.  Intravascular coagulation and the liver.

Authors:  A L Bloom
Journal:  Br J Haematol       Date:  1975-05       Impact factor: 6.998

2.  [A SCREENING-TEST, FOLLOWED BY A RAPID QUANTITATIVE MICRODETERMINATION OF PLASMA FIBRINOGEN].

Authors:  T STRENGERS; E G ASBERG
Journal:  Ned Tijdschr Geneeskd       Date:  1963-11-02

3.  INHERITED ANTITHROMBIN DEFICIENCY CAUSING THROMBOPHILIA.

Authors:  O EGEBERG
Journal:  Thromb Diath Haemorrh       Date:  1965-06-15

4.  The theory of tracer experiments with 131I-labelled plasma proteins.

Authors:  C M MATTHEWS
Journal:  Phys Med Biol       Date:  1957-07       Impact factor: 3.609

5.  Fibrinogen survival in cirrhosis: improvement by "low dose" heparin.

Authors:  M Coleman; N Finlayson; R E Bettigole; D Sadula; M Cohn; M Pasmantier
Journal:  Ann Intern Med       Date:  1975-07       Impact factor: 25.391

6.  Deficiency of antithrombin 3 activity associated with hereditary thrombosis tendency.

Authors:  E von Kaulla; K N von Kaulla
Journal:  J Med       Date:  1972

7.  Effect of peritoneovenous shunting with the Le Veen valve on ascites, renal function, and coagulation in six patients with intractable ascites.

Authors:  J D Ansley; R A Bethel; P A Bowen; W D Warren
Journal:  Surgery       Date:  1978-02       Impact factor: 3.982

Review 8.  Alpha 2-macroglobulin and antithrombin-heparin cofactor: modulators of hemostatic and inflammatory reactions. Alpha 2-macroglobulin.

Authors:  P C Harpel; R D Rosenberg
Journal:  Prog Hemost Thromb       Date:  1976

9.  SERUM ALBUMIN TURNOVER IN NORMAL SUBJECTS AND PATIENTS WITH CIRRHOSIS MEASURED BY 131I-LABELLED HUMAN ALBUMIN.

Authors:  P WILKINSON; C L MENDENHALL
Journal:  Clin Sci       Date:  1963-10       Impact factor: 6.124

10.  Direct evidence for Hageman factor (factor XII) activation by bacterial lipopolysaccharides (endotoxins).

Authors:  D C Morrison; C G Cochrane
Journal:  J Exp Med       Date:  1974-09-01       Impact factor: 14.307

View more
  4 in total

1.  Hepatocarcinoma in cirrhosis. Is antithrombin III a neoplastic marker?

Authors:  A Grieco; V De Stefano; A Cassano; A Ciabattoni; C Garufi; A Astone; G Leone; C Barone
Journal:  Dig Dis Sci       Date:  1991-07       Impact factor: 3.199

2.  Physiological changes of pregnancy and the Swansea criteria in diagnosing acute fatty liver of pregnancy.

Authors:  Adam Morton; Josephine Laurie
Journal:  Obstet Med       Date:  2018-04-16

3.  The influence of antithrombin III (AT III) substitution to supranormal activities on systemic procoagulant turnover in patients with end-stage chronic liver disease.

Authors:  R Scherer; M Kabatnik; J Erhard; J Peters
Journal:  Intensive Care Med       Date:  1997-11       Impact factor: 17.440

4.  Clinical Significance of Serum Antithrombin III Activity After Hepatectomy for Hepatocellular Carcinoma.

Authors:  Naruo Tokuyasu; Masataka Amisaki; Takehiko Hanaki; Yuki Murakami; Masaki Morimoto; Ei Uchinaka; Takuki Yagyu; Keisuke Goto; Tomoyuki Matsunaga; Manabu Yamamoto; Shuichi Takano; Teruhisa Sakamoto; Soichiro Honjo; Toshimichi Hasegawa; Yoshiyuki Fujiwara
Journal:  Yonago Acta Med       Date:  2021-04-15       Impact factor: 1.641

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.